Effects of glutathione S-transferase M1 and T1 deletions on carbamazepine metabolism among a Tunisian population

详细信息    查看全文

• 作者：Chahra Chbili ; Neila Fathallah ; Manel Nouira ; Aicha Laouani…
• 关键词：Glutathione ; S ; transferase M1 ; Glutathione ; S ; transferase T1 ; Carbamazepine ; Metabolism ; Genetic polymorphism ; Toxicity
• 刊名：Genes & Genomics
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：37
• 期：12
• 页码：991-997
• 全文大小：569 KB
• 参考文献：Albani F, Riva R, Baruzzi A (1995) Carbamazepine clinical pharmacology: a review. Pharmacopsychiatry 28:235-44CrossRef PubMed
  Askmark H, Wiholm B (1990) Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system. Acta Neurol Scand 81:131-40CrossRef PubMed
  Bertilsson L, Tomson T (1986) Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin Pharmacokinet 11:177-98CrossRef PubMed
  Bourgeois B, Wad N (1984) Individual and combined antiepileptic and neurotoxic activity of carbamazepine and carbamazepine-10,11-epoxide in mice. J Pharmacol Exp Ther 231:411-15PubMed
  Breton H, Cociglio M, Bressolle F, Peyriere H, Blayac JP, Hillaire-Buys D (2005) Liquid chromatography-electrospray mass spectrometry determination of carbamazepine, oxcarbazepine and eight of their metabolites in human plasm. J Chromatogr B Analyt Technol Biomed Life Sci 828:80-0CrossRef PubMed
  Bu HZ, Kang P, Deese AJ, Zhao P, Pool WF (2005) Human in vitro glutathionyl and protein adducts of carbamazepine-10,11-epoxide, a stable and pharmacologically active metabolite of carbamazepine. Drug Metab Dispos 33:1920-924CrossRef PubMed
  Bu HZ, Zhao P, Dalvie DK, Pool WF (2007) Identification of primary and sequential bioactivation pathways of carbamazepine in human liver microsomes using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 21:3317-322CrossRef PubMed
  Chbili C, Bannour S, Khlifi S, Ben Hadj Ali B, Saguem S (2014a) Relationships between pharmacokinetic parameters of carbamazepine and therapeutic response in patients with bipolar disease. Ann Biol Clin (Paris) 72:453-59
  Chbili C, B’chir F, M Ben Fredj, Saguem BN, Ben Amor S, Ben Ammou S, Saguem S (2014b) Effects of glutathione S-transferase M1 and T1 deletions on epilepsy risk among a Tunisian population. Epilepsy Res 108:1168-173CrossRef PubMed
  DeBethizy JD, Hayes JR (1988) Metabolism. A determinant of toxicity. In: Hayes AW (ed) Principles and methods of toxicology, 2nd edn. Raven Press, New York, pp 29-6
  Depondt C (2006) The potential of pharmacogenetics in the treatment of epilepsy. Eur J Paediatr Neurol 10:57-5CrossRef PubMed
  Ek Oh, Ban E, Woo JS, Kim CK (2006) Analysis of carbamazepine and its active metabolite, carbamazepine-10,11-epoxide, in human plasma using high-performance liquid chromatography. Anal Bioanal Chem 386:1931-936CrossRef
  Ferraro TN, Buono RJ (2005) The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview. Epilepsy Behav 7:18-6CrossRef PubMed
  Hayes JD, Flanagan JU, Jowsey IR (2005) Glutathione transferases. Annu Rev Pharmacol Toxicol 45:51-8CrossRef PubMed
  Hung CC, Chang WL, Ho JL, Tai JJ, Hsieh TJ, Huang HC, Hsieh YW, Liou HH (2012) Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Pharmacogenomics 13:159-69CrossRef PubMed
  Kalapos MP (2002) Carbamazepine-provoked hepatotoxicity and possible aetiopathological role of glutathione in the events. Retrospective review of old data and call for new investigation. Adverse Drug React Toxicol Rev 21:123-41CrossRef PubMed
  Kaniwa N, Saito Y (2013) The risk of cutaneous adverse reactions among patients with the HLA-A* 31:01 allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: a perspective review. Ther Adv Drug Saf 4:246-53PubMedCentral CrossRef PubMed
  Koch MW, Polman SK (2009) Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev 7:CD006453
  Korinthenberg R, Haug C, Hannak D (1994) The Metabolization of Carbamazepine to CBZ-10,11-Epoxide in Children from the Newborn Age to Adolescence. Neuropediatrics 25:214-16CrossRef PubMed
  Lin HJ, Han CY, Bernstein DA, Hsiao W, Lin BK, Hardy S (1994) Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis 15:1077-081CrossRef PubMed
  Liu H, Delgado MR (1994) The influence of polytherapy on the relationships between serum carbamazepine and its metabolites in epileptic children. Epilepsy Res 17:257-69CrossRef PubMed
  Munaka M, Kohshi K, Kawamoto T, Takasawa S, Nagata N, Itoh H, Oda S, Katoh T (2003) Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma. J Cancer Res Clin Oncol 129:355-60CrossRef PubMed
  Pearce RE, Vakkalagadda GR, Leeder JS (2002) Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab Dispos 30:1170-179CrossRef PubMed
  Pirmohamed M, Kitteringham NR, Guenthner TM, Breckenridge AM, Park BK (1992) An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazep
• 作者单位：Chahra Chbili (1)
  Neila Fathallah (1)
  Manel Nouira (1)
  Aicha Laouani (1)
  Anis Hassine (2)
  Sana Ben Amor (2)
  Sofiene Ben Ammou (2)
  Saad Saguem (1)
  
  1. Metabolic Biophysics, Professional Toxicology and Applied Environmental Laboratory, Department of Biophysics, Medicine Faculty of Sousse, Sousse University, Avenue Mohamed Karoui, Sousse, 4002, Tunisia
  2. Neurology Department of Central Hospital University (CHU), Sousse University, Sousse, 4002, Tunisia
  
• 刊物主题：Microbial Genetics and Genomics; Plant Genetics & Genomics; Animal Genetics and Genomics; Human Genetics;
• 出版者：Springer Netherlands
• ISSN：2092-9293

文摘

Glutathione-S-transferases enzymes are involved in the detoxification of several endogenous and exogenous substances. These genetic pathways could be involved in the therapeutic efficacy and toxic effects of carbamazepine by modulating metabolic profiles. In this present study, we evaluated the effects of two glutathione-S-transferase polymorphisms, GSTM1 and GSTT1, on metabolic phenotype of carbamazepine in a Tunisian population. These polymorphisms were studied in 94 patients with epilepsy, using a polymerase chain reaction. Test U Mann–Whitney was used for analyzing results. The study results demonstrated that individuals with the glutathione-S-transferase M1 null genotype were at an increased risk of toxicity secondary to a relative accumulation of carbamazepine 10,11-epoxide and carbamazepine. Consequently leading to an increase in the plasma concentration of carbamazepine and carbamazepine 10,11-epoxide (P = 0.03, P = 0.01 respectively). Whereas no significant effects were observed between individuals with glutathione-S-transferase M1 or glutathione-S-transferase T1 null genotype and metabolic ratio carbamazepine 10,11-epoxide to carbamazepine (P = 0.40). These genotyping findings revealed that the absence of GSTM1 activity could be a contributor factor for the development of toxic effects of carbamazepine. Such an accumulation would require eventually a dosage adjustment. Keywords Glutathione-S-transferase M1 Glutathione-S-transferase T1 Carbamazepine Metabolism Genetic polymorphism Toxicity